Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.39) by 50 percent. This is a 92.08 percent increase over losses of $(2.40) per share from the same period last year.